Pupil size affects coma value in certain eyes

Article

When compared with eyes of normal axial length, high-myopic pseudophakic eyes with posterior staphyloma had significantly less internal coma and less coma variations during mydriasis, according to recently published research.

When compared with eyes of normal axial length, high-myopic pseudophakic eyes with posterior staphyloma had significantly less internal coma and less coma variations during mydriasis, according to research published in Eye.

The researchers studied 60 eyes: 40 in highly myopic cataract patients with posterior staphyloma and 20 in cataract patients with normal axial length.

They found that the high-myopic pseudophakic eyes with posterior staphyloma had significantly lower values of internal coma - both under 4 mm and 6 mm pupil sizes - at 1 month after phacoemulsification and IOL implantation compared to eyes with normal axial length.

The high-myopic pseudophakic eyes with posterior staphyloma also had significantly lower internal total higher-order aberrations and third-order aberrations at 6-mm pupil size.

In addition, the researchers found statistically significant differences between the two groups in the variation from 4- to 6-mm pupil sizes for:

  • internal coma
  • internal third-order aberrations

  • internal total higher-order aberrations
  • ocular coma aberrations.

Strehl ratio increased significantly in high-myopic eyes and decreased slightly in normal axial length eyes after mydriasis, and modular transfer functions were found to vary in a statistically significant manner between the two groups at frequencies of 15, 30, 45 and 60 cycles/degree.

To read an abstract of the study, click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.